Header Logo

Connection

JENNIFER WARGO to Drug Resistance, Neoplasm

Back to Details
This is a "connection" page, showing publications JENNIFER WARGO has written about Drug Resistance, Neoplasm.
JENNIFER WARGO
Connection Strength
2.262
Drug Resistance, Neoplasm
  1. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021 10 14; 184(21):5309-5337.
    View in: PubMed
    Score: 0.289
  2. Interaction of molecular alterations with immune response in melanoma. Cancer. 2017 06 01; 123(S11):2130-2142.
    View in: PubMed
    Score: 0.214
  3. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
    View in: PubMed
    Score: 0.200
  4. Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells. Nature. 2023 Aug; 620(7974):651-659.
    View in: PubMed
    Score: 0.082
  5. Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance. Nature. 2023 05; 617(7960):377-385.
    View in: PubMed
    Score: 0.081
  6. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun. 2021 09 23; 12(1):5606.
    View in: PubMed
    Score: 0.072
  7. Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nat Commun. 2021 01 12; 12(1):346.
    View in: PubMed
    Score: 0.069
  8. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat Immunol. 2019 09; 20(9):1231-1243.
    View in: PubMed
    Score: 0.062
  9. A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov. 2018 05; 8(5):556-567.
    View in: PubMed
    Score: 0.056
  10. The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. Clin Cancer Res. 2018 07 15; 24(14):3366-3376.
    View in: PubMed
    Score: 0.056
  11. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nat Commun. 2017 09 19; 8(1):607.
    View in: PubMed
    Score: 0.055
  12. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017 09 15; 357(6356):1156-1160.
    View in: PubMed
    Score: 0.055
  13. Hallmarks of response to immune checkpoint blockade. Br J Cancer. 2017 Jun 27; 117(1):1-7.
    View in: PubMed
    Score: 0.053
  14. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379).
    View in: PubMed
    Score: 0.053
  15. Loss of IFN-? Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016 Oct 06; 167(2):397-404.e9.
    View in: PubMed
    Score: 0.051
  16. Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma. Mol Cancer Ther. 2016 10; 15(10):2442-2454.
    View in: PubMed
    Score: 0.050
  17. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 2016 Apr 14; 532(7598):250-4.
    View in: PubMed
    Score: 0.049
  18. Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. Cell Rep. 2015 Jun 09; 11(9):1458-73.
    View in: PubMed
    Score: 0.047
  19. MITF Modulates Therapeutic Resistance through EGFR Signaling. J Invest Dermatol. 2015 Jul; 135(7):1863-1872.
    View in: PubMed
    Score: 0.046
  20. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. Cancer Discov. 2015 Mar; 5(3):274-87.
    View in: PubMed
    Score: 0.045
  21. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci Signal. 2014 12 23; 7(357):ra121.
    View in: PubMed
    Score: 0.045
  22. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 2014 Jul; 4(7):816-27.
    View in: PubMed
    Score: 0.043
  23. PDGFRa up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget. 2014 Apr 15; 5(7):1926-41.
    View in: PubMed
    Score: 0.043
  24. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 2014 Jan; 4(1):61-8.
    View in: PubMed
    Score: 0.042
  25. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature. 2013 Dec 05; 504(7478):138-42.
    View in: PubMed
    Score: 0.042
  26. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov. 2013 Dec; 3(12):1378-93.
    View in: PubMed
    Score: 0.042
  27. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A. 2013 Mar 12; 110(11):4321-6.
    View in: PubMed
    Score: 0.040
  28. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res. 2013 Feb 01; 19(3):598-609.
    View in: PubMed
    Score: 0.039
  29. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012 Jul 26; 487(7408):500-4.
    View in: PubMed
    Score: 0.038
  30. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011 Nov 23; 480(7377):387-90.
    View in: PubMed
    Score: 0.036
  31. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010 Dec 16; 468(7326):968-72.
    View in: PubMed
    Score: 0.034
  32. Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Res. 2019 Oct; 29(10):846-861.
    View in: PubMed
    Score: 0.016
  33. Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discov. 2017 08; 7(8):832-851.
    View in: PubMed
    Score: 0.013
  34. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol. 2016 Aug 01; 2(8):1056-64.
    View in: PubMed
    Score: 0.013
  35. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. Cancer Cell. 2016 Mar 14; 29(3):270-284.
    View in: PubMed
    Score: 0.012
  36. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.
    View in: PubMed
    Score: 0.012
  37. Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. PLoS One. 2015; 10(10):e0140310.
    View in: PubMed
    Score: 0.012
  38. Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest. 2015 Apr; 125(4):1459-70.
    View in: PubMed
    Score: 0.011
  39. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015 Mar; 47(3):250-6.
    View in: PubMed
    Score: 0.011
  40. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1a and oxidative phosphorylation in melanoma. Cancer Res. 2014 Dec 01; 74(23):7037-47.
    View in: PubMed
    Score: 0.011
  41. Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One. 2014; 9(7):e101286.
    View in: PubMed
    Score: 0.011
  42. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 2013 Mar; 3(3):338-49.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.